Biomarkers
SE
The mean (SE) incremental changes in Aβ-albumin complex blood levels’ concentration were 1.22 (0.89) mg/mL in the placebo group (n = 76) and 3.95 (1.10) mg/mL in the cilostazol group (n = 67) (Figure 3A). In the ANCOVA for change in the Aβ-albumin complex blood levels, a significant interaction was found between the treatment group and placebo group in the baseline value of the Aβ-albumin complex blood level (Figure 3B). The cilostazol group showed a significant negative correlation of the Aβ-albumin complex blood levels’ concentration between baseline and the 24-week visit (Pearson correlation coefficient, −0.34; 